Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Megakaryocyte and platelet thrombospondin-1 regulates matrix remodeling by stabilizing basement membrane COL6A1 in lung injury.

Nature communications·2026

Same author

Distinct contributions of Etv2<sup>+</sup> and Flk1<sup>+</sup> progenitors to endothelial, hematopoietic, and cardiac lineages.

Cell reports·2025

Same author

Linking tumour angiogenesis and tumour immunity.

Nature reviews. Immunology·2025

Same author

BCLAF1 restrains stress responses in hematopoietic stem cells to support expansion and repopulation.

Blood advances·2025

Same author

Transcriptional and chromatin accessibility landscapes of hematopoiesis in a mouse model of breast cancer.

Journal of immunology (Baltimore, Md. : 1950)·2025

Same author

ZBTB46 coordinates angiogenesis and immunity to control tumor outcome.

Nature immunology·2024

Search research articles

Related Experiment Video

Updated: Jun 6, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Enhancing tumor immunity via in vivo cDC1 reprogramming.

Yoojung Kwon¹, Kyunghee Choi¹

¹Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.

Trends in Immunology

|November 22, 2024

Summary

Reprogramming tumor cells into dendritic cell-like cells in situ creates an immune-attracting tumor environment. This approach shows promise for effective tumor-specific cancer immunotherapy.

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Related Experiment Videos

Last Updated: Jun 6, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Area of Science:

Immunology
Oncology
Gene Therapy

Background:

The tumor microenvironment often suppresses anti-tumor immunity.
Conventional dendritic cells (cDCs) are crucial for initiating adaptive anti-tumor immune responses.

Purpose of the Study:

To investigate the potential of in situ reprogramming of tumor cells into cDC-like cells.
To assess the impact of this reprogramming on the tumor microenvironment and anti-tumor immunity.

Main Methods:

Utilized viral vectors to deliver transcription factors for reprogramming tumor cells.
Administered reprogramming factors directly into the tumor site (in situ).
Analyzed the resulting tumor microenvironment for immune cell infiltration and activation.

Main Results:

Successful reprogramming of tumor cells into cDC-like cells was achieved.
Reprogrammed tumors exhibited enhanced T cell recruitment and activation.
An immunogenic tumor microenvironment was established, promoting anti-tumor immunity.

Conclusions:

In situ reprogramming of tumor cells into cDC-like cells is a viable strategy.
This method effectively enhances the anti-tumor immune response.
It holds significant potential for developing novel tumor-specific cancer immunotherapies.